Koyfin Home > Directory > Health Care > Adverum Biotechnlgs > Long-term Debt / Equity

Adverum Biotechnlgs Long-term Debt / Equity Chart (ADVM)

Adverum Biotechnlgs annual/quarterly Long-term Debt / Equity from 2014 to 2020.
  • Adverum Biotechnlgs Long-term Debt / Equity for the quarter ending June 06, 2020 was $10m a -47.59% decrease of -5m year over year
  • Adverum Biotechnlgs Long-term Debt / Equity for the last 12 months ending June 06, 2020 was $10m a -47.59% decrease of -5m year over year
  • Adverum Biotechnlgs Annual Long-term Debt / Equity for 2019 was $16m a 99.39% increase of 16m from 2018
  • Adverum Biotechnlgs Annual Long-term Debt / Equity for 2018 was $0m a -149.80% decrease of 0m from 2017
  • Adverum Biotechnlgs Annual Long-term Debt / Equity for 2017 was $0m a 86.19% increase of 0m from 2016
Other Ratios Metrics:
  • Adverum Biotechnlgs Total Debt / Capital for the quarter ending December 12, 2017 was $0m a 56.92% increase of 0m year over year
  • Adverum Biotechnlgs Other Liabilities for the quarter ending December 12, 2018 was $2m a -14.42% decrease of 0m year over year
  • Adverum Biotechnlgs Total Debt / Equity for the quarter ending December 12, 2017 was $0m a 56.98% increase of 0m year over year
View Chart On Koyfin

Quarterly ADVM Long-term Debt / Equity Data

06/2020$10m
03/2020$9m
12/2019$16m
09/2019$14m
06/2019$12m
03/2019$12m
12/2018$0m
12/2017$0m
09/2017$0m
06/2017$0m

Annual ADVM Long-term Debt / Equity Data

2019$16m
2018$0m
2017$0m
2016$0m
2012$-50m